Domsil®

Domperidone Tablet/Suspension

Description: Domsil® is Dopamine antagonist. As it does not readily enter the central nervous system, its effects are confirmed to the periphery and acts principally at the receptor in the Chemoreceptor Trigger Zone (CTZ). **Presentation: Domsil®** Tablet: Each tablet contains Domperidone Maleate BP equivalent to 10 mg Domperidone BP. **Domsil® Suspension:** Each 5 ml contains 5 mg of Domperidone BP. **Indications:** 01. Stimulation of gut mobility: (a) Non-ulcer dyspepsia; (b) Esophageal reflux, reflux esophagitis and gastritis; (c) Diabetic gastroparesis; (d) Functional dyspepsia; (e) Speeding barium transit in 'follow-through' radiological studies; 02. Prevention and symptomatic relief of acute nausea and vomiting from any cause including cytotoxic therapy, radiotherapy and anti-parkinsonism therapy; 03. In the symptomatic treatment of migraine. **Dosage and administration:** The recommended oral dose for **Adults:** 10-20 mg every 4-8 hours daily. **Children:** 0.2-0.4 mg/kg every 4-8 hours daily. [Nausea and vomiting following cytotoxic therapy or radiotherapy only] Note: **Domsil®** tablet and suspension should be taken 15-30 minutes before a meal. For acute nausea and vomiting, maximum period of treatment is 12 weeks. **Contraindications:** Domperidone is contraindicated to patients who have known hypersensitivity to this drug and in case of neonates.

Precautions: Domperidone should be used with absolute caution in case of children because there may be an increased risk of extra-pyramidal reactions in young children because of an incompletely developed blood-brain barrier. **Side-effects:** Domperidone may produce hyperprolactinemia (1.3% frequency). This may result in galactorrhea, breast enlargement and soreness and reduced libido. Dry mouth (1.9%), thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with Domperidone. Extra-pyramidal reactions are seen in 0.05% of patients in clinical studies. **Use in pregnancy & lactation: Pregnant women:** The safety of Domperidone has not been proven and it is therefore not recommended during pregnancy. Animal studies have not demonstrated teratogenic effects on the fetus. **Lactating mother:** Domperidone may precipitate galactorrhea and improve post-natal lactation. It is secreted in breast milk but in very small quantities insufficient to be considered harmful. **Drug Interactions:** Domperidone may reduce the hypoprolactinemic effect of bromocriptine. The action of Domperidone on GIT function may be antagonized by anti-muscarinics and opioid analgesics. **Over Dosage:** There are no reported cases of over dosage. **How Supplied: Domsil®** Tablet: Box containing 10X10's tablets in blister pack. **Domsil®** Suspension: Each bottle contains 60 ml & 100 ml of suspension.

Manufactured by :
Silva
Pharmaceuticals Limited
Maijdee, Noakhali, Bangladesh